Journal of Pediatric and Adolescent Gynecology
Volume 19, Issue 6 , Pages 363-371 , December 2006

Dysmenorrhea in Adolescents and Young Adults: Etiology and Management

  • Zeev Harel, MD

      Affiliations

    • Corresponding Author InformationAddress correspondence to: Zeev Harel, MD, Division of Adolescent Medicine, Hasbro Children's Hospital, 593 Eddy Street, Providence, RI 02903

References 

  1. Herman-Giddens ME, Slora EJ, Wasserman RC, et al. Secondary sexual characteristics and menses in young girls seen in office practice: A study from the Pediatric Research in Office Settings. Pediatrics. 1997;99:505
  2. Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in girls. Arch Dis Child. 1969;44:291
  3. Hallberg L, Hogdahl AM, Nilsson L, et al. Menstrual blood loss: a population study. Acta Obstet Gynecol Scand. 1966;45:320
  4. Apter D, Vihko R. Early menarche: A risk factor for breast cancer, indicates early onset of ovulatory cycles. J Clin Endocrinol Metab. 1983;57:82
  5. Klein JR, Litt IF. Epidemiology of adolescent dysmenorrhea. Pediatrics. 1981;68:661
  6. Campbell MA, McGrath PJ. Non-pharmacologic strategies used by adolescents for the management of menstrual discomfort. Clin J Pain. 1999;15:313
  7. Andersch B, Milsom I. An epidemiologic study of young women with dysmenorrhea. Am J Obstet Gynecol. 1982;144:655
  8. Johnson J. Level of knowledge among adolescent girls regarding effective treatment for dysmenorrhea. J Adolesc Health. 1988;9:398
  9. Campbell MA, McGrath PJ. Use of medication by adolescents for the management of menstrual discomfort. Arch Pediatr Adolesc Med. 1997;151:905
  10. Hillen TI, Grbavac SL, Johnston PJ, et al. Primary dysmenorrhea in young western Australian women: Prevalence, impact and knowledge of treatment. J Adolesc Health. 1999;25:40
  11. Balbi C, Musone R, Menditto A, et al. Influence of menstrual factors and dietary habits on menstrual pain in adolescence age. Eur J Obstet Gynecol Reprod Biol. 2000;91:143
  12. Deutch B. Menstrual pain in Danish women correlated with low n-3 polyunsaturated fatty acid intake. Eur J Clin Nutr. 1995;49:508
  13. Hornsby PP, Wilcox AJ, Weinber CR. Cigarette smoking and disturbance of menstrual function. Epidemiology. 1998;9:193
  14. Alvin PE, Litt IF. Current status of etiology and management of dysmenorrhea in adolescents. Pediatrics. 1982;70:516
  15. Simopoulos AP. Omega-3 fatty acids in health and disease and in growth and development. Am J Clin Nutr. 1991;54:438
  16. Chan WY, Hill JC. Determination of menstrual prostaglandin levels in nondysmenorrheic and dysmenorrheic subjects. Prostaglandins. 1978;15:365
  17. Rees MCP, Anderson ABM, Demers LM, et al. Prostaglandins in menstrual fluid in menorrhagia and dysmenorrhea. Br J Obstet Gynaecol. 1984;91:673
  18. Lundstrom V, Green K. Endogenous levels of prostaglandin F2α and its main metabolites in plasma and endometrium of normal and dysmenorrheic women. Am J Obstet Gynecol. 1978;130:640
  19. Rees MCP, Di Marzo V, Tippins JR, et al. Leukotriene release by endometrium and myometrium throughout the menstrual cycle in dysmenorrhea and menorrhagia. J Endocrinol. 1987;113:291
  20. Levinson SL. Peptidoleukotriene binding in guinea pig uterine membrane preparations. Prostaglandins. 1984;28:229
  21. Nigam S, Benedetto C, Zonca M, et al. Increased concentrations of eicosanoids and platelet-activating factor in menstrual blood from women with primary dysmenorrhea. Eicosanoids. 1991;4:137
  22. Harel Z, Lilly C, Riggs S, et al. Urinary leukotriene (LT)-E4 in adolescents with dysmenorrhea. J Adolesc Health. 2000;27:151
  23. Laufer MR, Goitein L, Bush M, et al. Prevalence of endometriosis in adolescent women with chronic pelvic pain not responding to conventional therapy. J Pediatr Adolesc Gynecol. 1997;10:199
  24. Goldstein DP, DeCholnoky C, Leventhal JM, et al. New insights into the old problem of chronic pelvic pain. J Pediatr Surg. 1979;14:675
  25. Simpson JL, Elias S, Malinak LR, et al. Heritable aspects of endometriosis: I. Genetic studies. Am J Obstet Gynecol. 1980;137:327
  26. Bulun SE, Yang S, Fang Z, et al. Estrogen production and metabolism in endometriosis. Ann N Y Acad Sci. 2002;955:75
  27. Matsuzaki S, Murakami T, Uehara S, et al. Expression of estrogen receptor alpha and beta in periotoneal and ovarian endometriosis. Fertil Steril. 2004;75:1198
  28. Keenan JA, Chen TT, Chadwell NL, et al. IL-1 beta, TNF-alpha and IL-2 in peritoneal fluid and macrophage-conditioned media of women with endometriosis. Am J Reprod Immunol. 1995;34:381
  29. Ota H, Igarashi S, Sasaki M, et al. Distribution of cyclooxygenase-2 in eutopic and ectopic endometrium in endometriosis and adenomyosis. Hum Reprod. 2001;16:561
  30. Tamura M, Deb S, Sebastian S, et al. Estrogen up-regulates cyclooxygenase-2 via estrogen receptor in human uterine microvascular endothelial cells. Fertil Steril. 2004;81:1351
  31. Noble LS, Takayama K, Zeitoun KM, et al. Prostaglandin E2 stimulates aromatase expression in endometriosis-derived stromal cells. J Clin Endocrinol Metab. 1997;82:600
  32. Zeitoun K, Takayama K, Sasano H, et al. Deficient 17B-hydroxysteroid dehydrogenase type 2 expression in endometriosis: failure to metabolize estradiol-17B. J Clin Endocrinol Metab. 1998;83:4474
  33. Chapron C, Fauconnier A, Dubuisson JB, et al. Deep infiltrating endometriosis; relation between severity of dysmenorrhea and extent of disease. Hum Reprod. 2003;18:760
  34. Fedele L, Parazzini F, Bianchi S, et al. Stage and localization of pelvic endometriosis and pain. Fertil Steril. 1990;53:155
  35. Goldstein DP, DeCholnoky C, Emans SJ. Adolescent endometriosis. J Adolesc Health Care. 1980;1:37
  36. Kotani N, Sakai I, Hashimoto H, et al. Analgesic effect of an herbal medicine for treatment of primary dysmenorrhea–a double blind study. Am J Chin Med. 1997;25:205
  37. Kaplan B, Rabinerson D, Lurie S, et al. Clinical evaluation of a new model of transcutaneous electrical nerve stimulation device for the management of primary dysmenorrhea. Gynecol Obstet Invest. 1997;44:255
  38. Steinberger A. The treatment of dysmenorrhea by acupuncture. Am J Chin Med. 1981;9:57
  39. Golub LJ, menduke H, Lang WR. Exercise and dysmenorrhea in young teenagers: a 3-year study. Obstet Gynecol. 1968;32:508
  40. Akin MD, Weingand KW, Hengehold DA, et al. Continuous low-level topical heat in the treatment of dysmenorrhea. Obstet Gynecol. 2001;97:343
  41. Barnard ND, Scialli AR, Hurlock D, et al. Diet and sex-hormone binding globulin, dysmenorrhea, and premenstrual symptoms. Obstet Gynecol. 2000;95:245
  42. Harel Z, Biro FM, Kotenhahn RK, et al. Supplementation with omega-3 fatty acids in the management of dysmenorrhea in adolescents. Am J Obstet Gynecol. 1996;174:1335
  43. Boctor AM, Eickolt M, Pugsley TA. Meclofenamate sodium is an inhibitor of both the 5- lipoxygenase and cycloxygenase pathways of the arachidonic acid cascade in vitro. Prostaglandins Leukot Med. 1986;23:229
  44. Chan WY, Dawood MY. Prostaglandin levels in menstrual fluid of nondysmenorrheic and of dysmenorrheic subjects with and without oral contraceptive or ibuprofen therapy. Adv Prostaglandin Thromboxane Res. 1980;8:1443
  45. Hanson FW, Izu A, Henzyl MR. Naproxen sodium in dysmenorrhea: its influence in allowing work/school activities. Obstet Gynecol. 1978;52:583
  46. Budoff PW. Zomepirac sodium in the treatment of primary dysmenorrhea syndrome. N Engl J Med. 1982;307:714
  47. Smith RP, Powell JR. Intrauterine pressure changes during dysmenorrhea therapy. Am J Obstet Gynecol. 1982;143:286
  48. Mehlisch DR. Ketoprofen, ibuprofen, and placebo in the treatment of primary dysmenorrhea: a double-blind crossover comparison. J Clin Pharmacol. 1988;28:S29
  49. Mehlisch DR. Double-blind crossover comparison of ketoprofen, naproxen, and placebo in patients with primary dysmenorrhea. Clin Ther. 1990;12:398
  50. Marchini M, Tozzi L, Bakshi R, et al. Comparative efficacy of diclofenac dispersible 50 mg and ibuprofen 400 mg in patients with primary dysmenorrhea. A randomized, double blind, within-patient, placebo-controlled study. Int J Clin Pharmacol Ther. 1995;33:491
  51. Owen PR. Prostaglandin synthetase inhibitors in the treatment of primary dysmenorrhea. Am J Obstet Gynecol. 1984;148:96
  52. Roy S. A double-blind comparison of a propionic acid derivative (ibuprofen) and a fenamate (mefenamic acid) in the treatment of dysmenorrhea. Obstet Gynecol. 1983;61:628
  53. DuRant RH, Jay MS, Shofitt T. Factors influencing adolescents' responses to regimens of naproxen for dysmenorrhea. Am J Dis Child. 1985;139:489
  54. Harel Z. Cyclooxygenase (COX)-2 specific inhibitors in the treatment of dysmenorrhea. J Pediatr Adolesc Gynecol. 2004;17:75
  55. Dawood M. Non-steroidal anti-inflammatory drugs and changing attitudes toward dysmenorrhea. Am J Med. 1988;84:23
  56. Harel Z, Riggs S, Vaz R, et al. The use of the leukotriene receptor antagonist montelukast (Singulair) in the management of dysmenorrhea in adolescents. J Pediatr Adolesc Gynecol. 2004;17:183
  57. Bieglmayer C, Hofer G, Kainz , et al. Concentrations of various arachidonic acid metabolites in menstrual fluid are associated with menstrual pain and are influenced by hormonal contraceptives. Gynecol Endocrinol. 1995;9:307
  58. Hauksson A, Akerlund M, Forsling ML, et al. Plasma concentrations of vasopressin and a prostaglandin F2α metabolite in women with primary dysmenorrhea before and during treatment with a combined oral contraceptive. J Endocrinol. 1987;115:355
  59. Creatsas G, Deligeoroglou E, Zachari A, et al. Prostaglandins: PGFα, PGE2, 6-keto-PGF1α and TXB serum levels in dysmenorrheic adolescents before, during and after treatment with oral contraceptives. Eur J Obstet Gynecol Reprod Biol. 1990;36:292
  60. Ekstrom P, Juchnicka E, Laudanski T, et al. Effect of an oral contraceptive in primary dysmenorrhea—changes in uterine activity and reactivity to agonists. Contraception. 1989;40:39
  61. Ekstrom P, Akerlund M, Forsling M, et al. Stimulation of vasopressin release in women with primary dysmenorrhea and after oral contraceptive treatment—effect on uterine contractility. Br J Obstet Gynaecol. 1992;99:680
  62. Milsom I, Andersch B. Effect of various oral contraceptive combinations on dysmenorrhea. Gynecol Obstet Invest. 1984;17:284
  63. Larsson G, Milsom I, Lindstedt G, et al. The influence of a low-dose combined oral contraceptive on menstrual blood loss and iron status. Contraception. 1992;46:327
  64. Robinson JC, Plichata S, Weisman CS, et al. Dysmenorrhea and use of oral contraceptives in adolescent women attending a family planning clinic. Am J Obstet Gynecol. 1992;166:578
  65. Ulstein M, Svendsen E, Steier A, et al. Clinical experience with a triphasic oral contraceptive. Acta Obstet Gynecol Scand. 1984;63:233
  66. Weber-Diehl F, Unger R, Lachnit U. Triphasic combination of ethinyl estradiol and gestodene. Long-term clinical trial. Contraception. 1992;46:19
  67. Davis AR, Westhoff C, O'Connell K, et al. Oral contraceptives for dysmenorrhea in adolescent girls: A randomized trial. Obstet Gynecol. 2005;106:97
  68. Louden NR, Foxwell M, Potts DM, et al. Acceptability of an oral contraceptive that reduces the frequency of menstruation: The tri-cycle pill regimen. BMJ. 1977;2:487
  69. Sulak PJ, Cressman BE, Waldrop E, et al. Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms. Obstet Gynecol. 1997;89:179
  70. Guillebaud J. Reducing withdrawal bleeds. Lancet. 2000;355:2168
  71. Ortiz A, Hiroi M, Stancyk FZ, et al. Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of Depo-MPA. J Clin Endocrinol Metab. 1977;44:32
  72. Jain J, Dutton C, Nicosia A, et al. Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera. Contraception. 2004;70:11
  73. Harel Z, Biro F, Kollar L. Depo-Provera in adolescents: Effects of early second injection or prior oral contraception. J Adolesc Health. 1995;16:379
  74. Physician Information—Depo-Provera CI: Available: Http://www.fda.gov/medwatch/SAFETY/2004/DepoProvera_Label.pdf. Accessed January 27, 2005.
  75. Baldaszti E, Wimmer-Puchinger B, Loschke K. Acceptability of the long-term contraceptive levonorgestrel-releasing intrauterine system (Mirena®): a 3-year follow-up study. Contraception. 2003;67:87
  76. Harel Z, Riggs S, Vaz R, et al. Adolescents' experience with the combined estrogen and progestin transdermal contraceptive method Ortho Evra. J Pediatr Adolesc Gynecol. 2005;18:85
  77. Cox DJ, Meyer RG. Behavioral treatment parameters with primary dysmenorrhea. J Behav Med. 1978;1:297
  78. Chatman DL, Ward AB. Endometriosis in adolescents. J Reprod Med. 1982;27:156
  79. Cook AS, Rock JA. Role of laparoscopy in the treatment of endometriosis. Fertil Steril. 1991;55:663
  80. Propst AM, Laufer MR. Endometriosis in adolescents: incidence, diagnosis, and treatment. J Reprod Med. 1999;44:751
  81. Lubianca JN, Gordon CM, Laufer MR. “Add-back” therapy for endometriosis in adolescents. J Reprod Med. 1998;43:164
  82. Ailawadi RK, Jobanputra S, Kataria M, et al. Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate; a pilot study. Fertil Steril. 2004;81:290
  83. Amsterdam LL, Gentry W, Jobanputra S, et al. Anastrazole and oral contraceptives: a novel treatment for endometriosis. Fertil Steril. 2005;84:300
  84. Chwalisz K, Perez MC, Demanno D, et al. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocrine Reviews. 2005;26:423

PII: S1083-3188(06)00241-5

doi: 10.1016/j.jpag.2006.09.001

Journal of Pediatric and Adolescent Gynecology
Volume 19, Issue 6 , Pages 363-371 , December 2006

Article Tools

* Image Usage & Resolution